RBC Capital Markets Maintains Outperform Rating and Raises Price Target for Pyxis Oncology

Article summary

RBC Capital Markets reaffirmed its 'Outperform' rating on Pyxis Oncology and increased its price target from $6 to $7, citing progress in the company's clinical trial pipeline.